Abstract
Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3%) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.
| Original language | English |
|---|---|
| Pages (from-to) | 489-497 |
| Number of pages | 9 |
| Journal | Psychiatry and clinical neurosciences |
| Volume | 70 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 01-11-2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neuroscience(all)
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
Cite this
}
Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection : A prospective study. / Kawase, Kohei; Kondo, Kenji; Saito, Takeo; Shimasaki, Ayu; Takahashi, Atsushi; Kamatani, Yoichiro; Kawabe, Naoto; Hashimoto, Senju; Ikeda, Masashi; Kubo, Michiaki; Yoshioka, Kentaro; Iwata, Nakao.
In: Psychiatry and clinical neurosciences, Vol. 70, No. 11, 01.11.2016, p. 489-497.Research output: Contribution to journal › Article
TY - JOUR
T1 - Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection
T2 - A prospective study
AU - Kawase, Kohei
AU - Kondo, Kenji
AU - Saito, Takeo
AU - Shimasaki, Ayu
AU - Takahashi, Atsushi
AU - Kamatani, Yoichiro
AU - Kawabe, Naoto
AU - Hashimoto, Senju
AU - Ikeda, Masashi
AU - Kubo, Michiaki
AU - Yoshioka, Kentaro
AU - Iwata, Nakao
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3%) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.
AB - Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3%) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.
UR - http://www.scopus.com/inward/record.url?scp=84987654226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84987654226&partnerID=8YFLogxK
U2 - 10.1111/pcn.12424
DO - 10.1111/pcn.12424
M3 - Article
C2 - 27471075
AN - SCOPUS:84987654226
VL - 70
SP - 489
EP - 497
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
SN - 1323-1316
IS - 11
ER -